Amphastar Pharmaceuticals, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Amphastar Pharmaceuticals, Inc. (AMPH) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$7.24 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-10.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-10
- Amphastar Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$7.24M.
- Amphastar Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $17.60M.
- Amphastar Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $20.66M.
- Amphastar Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$6.48M, a 186.20% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $20.74M.
- Amphastar Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$4.89M, a 177.95% decline from fiscal 2016.
- Amphastar Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $6.28M.
- Amphastar Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$1.75M, a 112.32% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-03-31 | -$7.24M 10-Q · filed 2019-05-10 | $10.36M derived: sum of 2 quarters · filed 2019-05-10 | $31.03M derived: sum of 3 quarters · filed 2019-05-10 | $24.55M derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2018-12-31 | $17.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $38.27M derived: sum of 2 quarters · filed 2019-03-15 | $31.79M derived: sum of 3 quarters · filed 2019-03-15 | $20.74M 10-K · filed 2019-03-15 | ||||
| 2018-09-30 | $20.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $14.19M derived: sum of 2 quarters · filed 2018-11-09 | $3.14M 10-Q · filed 2018-11-09 | $1.81M derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2018-06-30 | -$6.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$17.52M 10-Q · filed 2018-08-09 | -$18.85M derived: sum of 3 quarters · filed 2019-05-10 | -$34.47M derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2018-03-31 | -$11.05M 10-Q · filed 2019-05-10 | -$12.37M derived: sum of 2 quarters · filed 2019-05-10 | -$28.00M derived: sum of 3 quarters · filed 2019-05-10 | -$20.48M derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2017-12-31 | -$1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | -$16.95M derived: sum of 2 quarters · filed 2019-03-15 | -$9.44M derived: sum of 3 quarters · filed 2019-03-15 | -$4.89M 10-K · filed 2019-03-15 | -$6.76M 10-K · filed 2018-03-14 | |||
| 2017-09-30 | -$15.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$8.11M derived: sum of 2 quarters · filed 2018-11-09 | -$3.57M 10-Q · filed 2018-11-09 | -$5.43M 10-Q · filed 2017-11-09 | $2.19M derived: sum of 4 quarters · filed 2019-03-15 | |||
| 2017-06-30 | $7.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $12.05M 10-Q · filed 2018-08-09 | $10.19M 10-Q · filed 2017-08-09 | $17.81M derived: sum of 3 quarters · filed 2019-03-15 | $17.75M derived: sum of 4 quarters · filed 2019-03-15 | |||
| 2017-03-31 | $4.54M 10-Q · filed 2018-05-10 | $4.41M 10-Q · filed 2017-05-10 | $10.30M derived: sum of 2 quarters · filed 2019-03-15 | $10.23M derived: sum of 3 quarters · filed 2019-03-15 | $13.56M derived: sum of 4 quarters · filed 2019-03-15 | |||
| 2016-12-31 | $5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $5.69M derived: sum of 2 quarters · filed 2019-03-15 | $9.02M derived: sum of 3 quarters · filed 2019-03-15 | $6.28M 10-K · filed 2019-03-15 | ||||
| 2016-09-30 | -$62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $3.27M derived: sum of 2 quarters · filed 2017-11-09 | $524.00K 10-Q · filed 2017-11-09 | -$4.08M derived: sum of 4 quarters · filed 2018-03-14 | ||||
| 2016-06-30 | $3.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $586.00K 10-Q · filed 2017-08-09 | -$4.02M derived: sum of 3 quarters · filed 2018-03-14 | -$7.80M derived: sum of 4 quarters · filed 2018-03-14 | ||||
| 2016-03-31 | -$2.74M 10-Q · filed 2017-05-10 | -$7.35M derived: sum of 2 quarters · filed 2018-03-14 | -$11.13M derived: sum of 3 quarters · filed 2018-03-14 | -$5.26M derived: sum of 4 quarters · filed 2018-03-14 | ||||
| 2015-12-31 | -$4.61M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$8.39M derived: sum of 2 quarters · filed 2018-03-14 | -$2.51M derived: sum of 3 quarters · filed 2018-03-14 | -$1.75M 10-K · filed 2018-03-14 | ||||
| 2015-09-30 | -$3.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $2.09M derived: sum of 2 quarters · filed 2016-11-09 | $2.85M 10-Q · filed 2016-11-09 | -$2.20M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2015-06-30 | $5.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $6.63M 10-Q · filed 2016-08-09 | $1.58M derived: sum of 3 quarters · filed 2017-03-15 | $10.38M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2015-03-31 | $760.00K 10-Q · filed 2016-05-10 | -$4.29M derived: sum of 2 quarters · filed 2017-03-15 | $4.51M derived: sum of 3 quarters · filed 2017-03-15 | $16.45M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2014-12-31 | -$5.05M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $3.75M derived: sum of 2 quarters · filed 2017-03-15 | $15.69M derived: sum of 3 quarters · filed 2017-03-15 | $14.24M 10-K · filed 2017-03-15 | ||||
| 2014-09-30 | $8.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $20.75M derived: sum of 2 quarters · filed 2015-11-13 | $19.29M 10-Q · filed 2015-11-13 | $20.94M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-06-30 | $11.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $10.49M 10-Q · filed 2015-08-13 | $12.14M derived: sum of 3 quarters · filed 2016-03-15 | $8.13M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-03-31 | -$1.45M 10-Q · filed 2015-05-14 | $191.00K derived: sum of 2 quarters · filed 2016-03-15 | -$3.82M derived: sum of 3 quarters · filed 2016-03-15 | |||||
| 2013-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$2.37M derived: sum of 2 quarters · filed 2016-03-15 | $3.37M 10-K · filed 2016-03-15 | |||||
| 2013-09-30 | -$4.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $1.73M 10-Q · filed 2014-11-13 | ||||||
| 2013-06-30 | $5.74M 10-Q · filed 2014-08-13 | |||||||
| 2012-12-31 | -$3.52M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |